|
1
|
Mackey JR, Martin M, Pienkowski T, et al;
TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and
cyclophosphamide in node-positive breast cancer: 10-year follow-up
of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 14:72–80.
2013.PubMed/NCBI
|
|
2
|
Fossella F, Pereira JR, von Pawel J, et
al: Randomized, multinational, phase III study of docetaxel plus
platinum combinations versus vinorelbine plus cisplatin for
advanced non-small-cell lung cancer: the TAX 326 study group. J
Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vermorken JB, Remenar E, van Herpen C, et
al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and
docetaxel in unresectable head and neck cancer. N Engl J Med.
357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
et al; V325 Study Group. Phase III study of docetaxel and cisplatin
plus fluorouracil compared with cisplatin and fluorouracil as
first-line therapy for advanced gastric cancer: a report of the
V325 Study Group. J Clin Oncol. 24:4991–4997. 2006.PubMed/NCBI
|
|
5
|
Yilmaz M, Demirdover C and Mola F:
Treatment options in extravasation injury: an experimental study in
rats. Plast Reconstr Surg. 109:2418–2423. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bowers DG Jr and Lynch JB: Adriamycin
extravasation. Plast Reconstr Surg. 61:86–92. 1978. View Article : Google Scholar
|
|
7
|
Dorr RT and Bool KL: Antidote studies of
vinorelbine-induced skin ulceration in the mouse. Cancer Chemother
Pharmacol. 36:290–292. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dorr RT, Snead K and Liddil JD: Skin
ulceration potential of paclitaxel in a mouse skin model in vivo.
Cancer. 78:152–156. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Payne AS, James WD and Weiss RB:
Dermatologic toxicity of chemotherapeutic agents. Semin Oncol.
33:86–97. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gallo E, Llamas-Velasco M, Navarro R,
Fraga J and García-Diez A: Eccrine squamous syringometaplasia
secondary to cutaneous extravasation of docetaxel: report of three
cases. J Cutan Pathol. 40:326–329. 2013.PubMed/NCBI
|
|
11
|
Kramer F, Schippert C, Rinnau F,
Hillemanns P and Park-Simon TW: The first description of
docetaxel-induced recall inflammatory skin reaction after previous
drug extravasation (February). Ann Pharmacother. Jan 25–2011.(Epub
ahead of print).
|
|
12
|
Ley BD, Millán GG, Perez JS, Fraga J and
Díez AG: Docetaxel recall phenomenon at the site of previous drug
extravasation. Arch Dermatol. 146:1190–1191. 2010.PubMed/NCBI
|
|
13
|
Cifuentes L, Ring J and Brockow K:
Extravasation of docetaxel. J Dtsch Dermatol Ges. 10:662–663.
2012.(In English, German).
|
|
14
|
Barceló R, Viteri A, Muñoz A, Carrera S,
Rubio I and López-Vivanco G: Extravasation of docetaxel: a red hand
syndrome. Arch Dermatol. 141:1326–1327. 2005.PubMed/NCBI
|
|
15
|
El Saghir NS and Otrock ZK: Docetaxel
extravasation into the normal breast during breast cancer
treatment. Anticancer Drugs. 15:401–404. 2004.PubMed/NCBI
|
|
16
|
Ho CH, Yang CH and Chu CY: Vesicant-type
reaction due to docetaxel extravasation. Acta Derm Venereol.
83:467–468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berghammer P, Pöhnl R, Baur M and Dittrich
C: Docetaxel extravasation. Support Care Cancer. 9:131–134. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Raley J, Geisler JP, Buekers TE and
Sorosky JI: Docetaxel extravasation causing significant delayed
tissue injury. Gynecol Oncol. 78:259–260. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ascherman JA, Knowles SL and Attkiss K:
Docetaxel (taxotere) extravasation: a report of five cases with
treatment recommendations. Ann Plast Surg. 45:438–441. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chu CY, Yang CH, Yang CY, Hsiao GH and
Chiu HC: Fixed erythrodysaesthesia plaque due to intravenous
injection of docetaxel. Br J Dermatol. 142:808–811. 2000.
View Article : Google Scholar : PubMed/NCBI
|
